ACXP
Acurx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+1.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.8B | 1.8B | 5.4M | 6.0M | 4.8M |
| SG&A Expense | 7.6B | 6.3B | 8.7M | 8.5M | 7.3M |
| General & Admin Expense | 7.6B | 6.3B | 8.7M | 8.5M | 7.3M |
| Selling & Marketing Expense | (1.6M) | — | — | — | — |
| Other Expenses | (9.5B) | (8.1B) | 0.00 | — | — |
| Total Operating Expenses | 7.7M | 8.1M | 14.1M | 14.6M | 12.1M |
| Cost and Expenses | 7.7M | 8.1M | 14.1M | 14.6M | 12.1M |
| Operating Income (EBIT) | (7.7M) | (8.1M) | (14.1M) | (14.6M) | (12.1M) |
| Non-Operating | |||||
| Interest Income | 162.8K | 125.4K | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 162.8K | 125.4K | — | — | — |
| Other Non-Op Income/Expense | 162.8K | 125.4K | 0.00 | — | — |
| Non-Operating Income (excl Interest) | (109.8K) | (125.4K) | (0.00) | — | — |
| EBT (Pre-Tax Income) | (7.5M) | (8.0M) | (14.1M) | (14.6M) | (12.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.5M) | (8.0M) | (14.1M) | (14.6M) | (12.1M) |
| Earnings from Cont. Ops | (7.5M) | (8.0M) | (14.1M) | (14.6M) | (12.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.5M) | (8.0M) | (14.1M) | (14.6M) | (12.1M) |
| Per Share | |||||
| Basic EPS | ($3.55) | ($5.32) | ($17.59) | ($23.01) | ($22.36) |
| Diluted EPS | ($3.55) | ($5.32) | ($17.59) | ($23.01) | ($22.36) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 4.3M | 1.5M | 851550 | 633600 | 540800 |
| Diluted Shares Outstanding | 4.3M | 1.5M | 851550 | 633600 | 540800 |
| Profitability Metrics | |||||
| EBITDA | (7.6M) | (8.0M) | — | (14.6M) | (12.1M) |
| D&A | — | — | 14.1M | — | — |
| EBIT | (7.6M) | (8.0M) | (14.1M) | (14.6M) | (12.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026